BioImage

BioImage was established in 1993 as a drug discovery research unit within Novo Nordisk. The research unit was led by Ole Thastrup and spun out of Novo Nordisk in 1999.

BioImage
TypePrivate
IndustryBiotechnology
Founded1999
HeadquartersSøborg
Key people
Patrik Dahlén, (CEO)
Steven Butcher, (CSO)
Len Pagliaro, (VP Business Development)
Edwin Moses (Chairman of the Board)
Axel Ullrich (Chairman of the Scientific Advisory Board)
ProductsProducts, services, and licensing around the proprietary Redistribution drug discovery technology
Revenue(not available)
Number of employees
42
Websitewww.bioimage.com

BioImage specializes in developing and selling proprietary bioassays to biopharmaceutical companies and research institutions. It also develops bioassays on a contract service basis.

BioImage has made broad patents covering Enhanced GFP (EGFP), GFP-based biosensors and any genetically encoded protein fusion to a luminophore, with subsequent monitoring of the protein's translocation within a cell as the primary readout for drug discovery assays. This intellectual property, trademarked Redistribution, allows many collaborations and out-licensing activities with biopharmaceutical companies.[1]

Merger

In April 2006, BioImage was acquired by Thermo Fisher Scientific.[2] The merger was complete in November 2006, and technology transfer to a US site was completed during 2007 and 2008.[3][4]

References
  1. "Life Technologies". www.bioimage.com. Retrieved 2017-04-24.
  2. "Thermo Scientific - US". www.thermofisher.com. Retrieved 2021-02-04.
  3. "Life Technologies" (PDF). www.bioimage.com. Retrieved 2017-04-24.
  4. "BioImage Company Profile: Acquisition & Investors | PitchBook". pitchbook.com. Retrieved 2021-02-04.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.